Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison - Centre de recherche Saint-Antoine - UMR S938 Accéder directement au contenu
Article Dans Une Revue Rheumatology Année : 2021

Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

Jérémie Sellam
Bruno Fautrel
Chi Duc Nguyen
  • Fonction : Auteur
Marie-Hélène Guyot
  • Fonction : Auteur
Nicolas Segaud
  • Fonction : Auteur
Laurent Marguerie
  • Fonction : Auteur
Xavier Deprez
  • Fonction : Auteur
Guy Baudens
  • Fonction : Auteur
Christophe Richez
Thao Pham

Résumé

Objectives: To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA.Methods: In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected.Results: A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts.Conclusion: In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.
Fichier principal
Vignette du fichier
article 15_hal.pdf (308.67 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03176959 , version 1 (15-04-2021)

Identifiants

Citer

Jean-Guillaume Letarouilly, Benoît Flachaire, Céline Labadie, Maéva Kyheng, Nicolas Cohen, et al.. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology, 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩. ⟨hal-03176959⟩
131 Consultations
368 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More